Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults
A clinical trial is underway to evaluate the effects of felzartamab on proteinuria in adults with IgAN.
Asset / Drug
Drug and asset intelligence for Felzartamab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.